Free Trial

Immunome (IMNM) Competitors

Immunome logo
$7.00 -0.28 (-3.85%)
As of 12:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IMNM vs. ACAD, MOR, RXRX, XENE, AMRX, CPRX, HCM, BHC, NAMS, and TWST

Should you be buying Immunome stock or one of its competitors? The main competitors of Immunome include ACADIA Pharmaceuticals (ACAD), MorphoSys (MOR), Recursion Pharmaceuticals (RXRX), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), Bausch Health Companies (BHC), NewAmsterdam Pharma (NAMS), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry.

Immunome vs.

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

In the previous week, Immunome had 13 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 27 mentions for Immunome and 14 mentions for ACADIA Pharmaceuticals. Immunome's average media sentiment score of 0.78 beat ACADIA Pharmaceuticals' score of 0.61 indicating that Immunome is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ACADIA Pharmaceuticals
8 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Immunome
8 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive

ACADIA Pharmaceuticals has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$957.80M2.98-$61.29M$1.3612.57
Immunome$9.04M67.32-$106.81M-$5.17-1.35

ACADIA Pharmaceuticals received 860 more outperform votes than Immunome when rated by MarketBeat users. However, 77.08% of users gave Immunome an outperform vote while only 73.05% of users gave ACADIA Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
ACADIA PharmaceuticalsOutperform Votes
897
73.05%
Underperform Votes
331
26.95%
ImmunomeOutperform Votes
37
77.08%
Underperform Votes
11
22.92%

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of Immunome shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ACADIA Pharmaceuticals has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, Immunome has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500.

ACADIA Pharmaceuticals currently has a consensus target price of $23.93, indicating a potential upside of 39.96%. Immunome has a consensus target price of $25.50, indicating a potential upside of 264.29%. Given Immunome's stronger consensus rating and higher possible upside, analysts plainly believe Immunome is more favorable than ACADIA Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ACADIA Pharmaceuticals
0 Sell rating(s)
8 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.50
Immunome
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

ACADIA Pharmaceuticals has a net margin of 13.83% compared to Immunome's net margin of -3,014.59%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Immunome's return on equity.

Company Net Margins Return on Equity Return on Assets
ACADIA Pharmaceuticals13.83% 25.83% 14.71%
Immunome -3,014.59%-48.63%-41.62%

Summary

ACADIA Pharmaceuticals beats Immunome on 11 of the 18 factors compared between the two stocks.

Remove Ads
Get Immunome News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMNM vs. The Competition

MetricImmunomePharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$608.66M$6.94B$5.64B$7.88B
Dividend YieldN/A2.73%4.57%4.01%
P/E Ratio-0.867.1323.1218.71
Price / Sales67.32225.38385.6791.56
Price / CashN/A65.6738.1634.64
Price / Book2.536.416.884.24
Net Income-$106.81M$141.90M$3.20B$247.06M
7 Day Performance-14.43%-4.37%-2.58%-1.76%
1 Month Performance-25.53%-6.78%1.93%-5.32%
1 Year Performance-71.64%-8.47%9.78%-0.51%

Immunome Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMNM
Immunome
1.9815 of 5 stars
$7.00
-3.8%
$25.50
+264.3%
-71.5%$608.66M$9.04M-0.8640Insider Trade
News Coverage
ACAD
ACADIA Pharmaceuticals
4.1536 of 5 stars
$17.20
-1.7%
$24.00
+39.5%
-5.5%$2.87B$957.80M22.05510
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730Positive News
RXRX
Recursion Pharmaceuticals
2.1987 of 5 stars
$6.84
+7.7%
$8.25
+20.6%
-41.3%$2.75B$58.49M-4.47400
XENE
Xenon Pharmaceuticals
2.3165 of 5 stars
$35.60
+0.8%
$57.38
+61.2%
-19.9%$2.72B$9.43M-12.62210
AMRX
Amneal Pharmaceuticals
3.4286 of 5 stars
$8.62
-1.5%
$10.80
+25.3%
+35.1%$2.67B$2.79B-12.687,700Positive News
CPRX
Catalyst Pharmaceuticals
4.8364 of 5 stars
$21.81
+3.8%
$32.50
+49.0%
+52.7%$2.65B$491.73M18.4880
HCM
HUTCHMED
2.4719 of 5 stars
$15.14
-3.5%
$19.00
+25.5%
-9.4%$2.64B$610.81M0.001,988
BHC
Bausch Health Companies
4.0873 of 5 stars
$7.06
-1.3%
$7.42
+5.1%
-35.7%$2.60B$9.63B-58.7920,270Options Volume
News Coverage
NAMS
NewAmsterdam Pharma
2.1106 of 5 stars
$23.34
-0.1%
$43.33
+85.7%
-1.3%$2.56B$45.56M-8.984Short Interest ↑
High Trading Volume
TWST
Twist Bioscience
4.0184 of 5 stars
$42.34
+6.0%
$54.40
+28.5%
+20.6%$2.53B$330.19M-12.53990
Remove Ads

Related Companies and Tools


This page (NASDAQ:IMNM) was last updated on 3/28/2025 by MarketBeat.com Staff
From Our Partners